



2014-05-15

**PRESS RELEASE**

**Oasmia recruits a new CFO**

**The Uppsala-based pharmaceutical company Oasmia Pharmaceutical AB (publ), listed on Nasdaq OMX, has employed Anders Lundin as its new CFO.**

Anders last employment was as Head of Finance at Q-Med in Uppsala. He has 21 years' experience in business administration of commercial businesses. Among others, he had been employed as Finance Manager at GE Healthcare, Zarlink Semiconductor, Hi3g Access AB and Elektronikgruppen AB. Anders has a Bachelor degree in Business Administration from Uppsala University.

The employment begins on August 11, 2014.

**For more information, please contact:**

Mikael Widell, Vice President Communications

Mobile: +46 70 311 99 60

E-mail: [mikael.widell@oasmia.com](mailto:mikael.widell@oasmia.com)

**Notes to editors:**

**About Oasmia Pharmaceutical AB**

Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics, which, in comparison with current alternatives, show improved properties, reduced side effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).

---

Information is also available at [www.oasmia.com](http://www.oasmia.com) [www.nasdaqomxnordic.com](http://www.nasdaqomxnordic.com) [www.boerse-frankfurt.de](http://www.boerse-frankfurt.de) [twitter.com/oasmia](https://twitter.com/oasmia)

*"Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 09.00, CET on May 15, 2014."*